The Criteria Used to Judge a Site
Part of Clinical Research Associate (CRA) Training: Site Identification and Feasibility.
About 6 minutes. Free, in your language, no account needed.
Why this matters
"Good site" is not an assessment. This lesson gives you the seven categories a site is judged on, what you look at in each, and the specific warning signs.
Use them as a checklist. Sites fail in predictable ways.
1. Investigator and staff
What you assess: the investigator's experience in the therapeutic area and in trials, the phases and populations they have worked with, the experience of coordinators and sub-investigators, current Good Clinical Practice training, the oversight structure, and staff availability and workload.
What you ask:
- Does the investigator have protected time for this trial, and how much?
- Is there adequate coordinator coverage, including a named backup?
- Has this team performed assessments or procedures like the ones this protocol requires?
- How many other trials is each person working on?
Warning signs: an investigator with heavy clinical duties and no protected time; a single coordinator with no backup; a team whose experience is all in a different therapeutic area; high recent staff turnover.
Investigator disengagement is the single most common root cause of a failing site, and it is visible at this stage if you ask directly rather than politely.
2. Patient population and recruitment feasibility
What you assess: the size and characteristics of the site's patient population, access to the specific disease group, historical recruitment performance, competing trials in the same population, recruitment strategy, ability to pre-screen, and resources for reaching a diverse population.
What you ask:
- Is the recruitment projection based on data or on hope?
- What did they actually enroll in their last comparable study, against what they projected?
- Which competing trials draw from the same patients?
- Do they have the diagnostic tools needed to establish eligibility?
- Can they reach the communities the trial needs, including in the languages those communities speak?
Warning signs: projections far above historical performance; no supporting numbers; several competing trials; a projection that assumes every eligible patient consents.
Sites with weak recruitment history rarely improve without a specific intervention.
3. Facilities, equipment and resources
What you assess: dedicated research space; investigational product storage that is temperature-controlled, monitored and access-restricted; calibrated equipment; laboratory access or an accredited partner laboratory; emergency equipment; and secure archive storage.
What you check: calibration records with dates; how temperature is monitored and what happens out of hours; who has access to product storage and how that is controlled; whether excursion procedures exist in writing.
Warning signs: a fridge with no alarm or no out-of-hours monitoring; calibration certificates that expired; product stored in a room anyone can enter; no defined archive.
4. Operational capacity and processes
A site can have excellent people and equipment and still fail operationally.
What you assess: written procedures for research activities; the consent process; data entry timelines; documented investigator oversight; staff turnover; and visit scheduling capacity.
What you ask: who does what when the coordinator is on leave; how a visit gets booked and who checks the window; how the investigator reviews safety data and how that review is recorded.
Warning signs: no backup coordinator; an investigator rarely present in clinic; procedures that exist on paper but that staff describe differently when asked.
5. Regulatory and ethics compliance
What you assess: ethics committee arrangements and typical turnaround times; inspection history where available; responsiveness to submissions; safety reporting processes; delegation logs; CVs and training files.
What you ask: has the site had regulatory findings, and what happened afterwards? How long does ethics review usually take here? How are safety letters filed and evidenced as reviewed?
Warning signs: disorganized regulatory files; slow or unpredictable ethics turnaround; a previous finding with no evidence of corrective action.
Note that a site with a past finding that it fixed properly may be safer than a site with no history at all.
6. Technology capability
What you assess: experience with electronic data capture; familiarity with randomization and supply systems; ability to use electronic patient-reported outcome, electronic consent and site management systems; reliable internet; and secure electronic records with audit trails.
What you ask: has the site struggled with data entry in previous trials? Who enters data and when? Is the connection reliable enough for remote monitoring access?
Warning signs: shared logins; no dedicated time for data entry; unreliable connectivity in a trial that depends on remote monitoring.
Do not treat unfamiliarity as disqualifying. Treat it as a training and support requirement to be costed and planned.
7. Financial and budget readiness
What you assess: the site's ability to manage a study budget, the reasonableness of its start-up fees, its history of financial disputes, and its ability to track pass-through costs.
CRAs do not negotiate budgets. You flag risks: a budget that will not fund the staffing the protocol requires is an operational risk, and it is your job to say so.
In practice
Leah assesses a candidate site for VT-301. On paper it is strong: experienced investigator, good patient numbers, modern facilities.
Two things do not fit. The calibration certificate for the electrocardiogram machine expired four months ago, and when she asks who covers the coordinator's annual leave, the answer is "we manage".
Neither is fatal. Both are specific.
Her report recommends the site conditionally, with two named actions: recalibrate and document the machine before activation, and identify and train a named backup coordinator. She scores the site moderate risk rather than low, and says why in one sentence each.
The sponsor selects the site with both conditions attached. Both are met before the initiation visit.
"We manage" is the most common answer and the least reassuring one. Ask for a name.
Key takeaways
- Sites are judged in seven categories: investigator and staff, patient population, facilities and equipment, operational capacity, regulatory compliance, technology, and financial readiness.
- Investigator disengagement is the most common root cause of a failing site, and it is detectable at assessment by asking directly about protected time.
- Compare projected recruitment with what the site actually achieved last time, because projections far above historical performance rarely materialize.
- A past regulatory finding that was properly corrected can be reassuring, whereas a disorganized file with no history is not.
- Unfamiliarity with systems is a costed training requirement, not a disqualification, but shared logins and no dedicated data entry time are genuine risks.